Investing.com - HTG Molecular Diagnostics (NASDAQ: HTGM) reported fourth quarter EPS of $-2.280, $1.93 worse than the analyst estimate of $-0.350. Revenue for the quarter came in at $1.03M versus the consensus estimate of $3.5M.
HTG Molecular Diagnostics's stock price closed at $2.650. It is down -42.140% in the last 3 months and down -63.260% in the last 12 months.
HTG Molecular Diagnostics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See HTG Molecular Diagnostics's stock price’s past reactions to earnings here.
According to InvestingPro, HTG Molecular Diagnostics's Financial Health score is "weak performance".
Check out HTG Molecular Diagnostics's recent earnings performance, and HTG Molecular Diagnostics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar